Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Carraro, Gianni (2007) Terapia dell'iperparatiroidismo secondario nei pazienti emodializzati. [Tesi di dottorato]

Full text disponibile come:

[img]
Anteprima
Documento PDF
2048Kb

Abstract (inglese)

Secondary hyperparathyroidism (SHPT) characterizes, by the first phases, the course of the chronic kidney disease and it has an important role in the phathogenesis of the osteitis fibrosa and the cardiovascular disease (that is responsible for the significant mortality in the uremic patients).
The traditional medical therapy of the secondary hyperparathyroidism (dietetics restriction of phosphorus, phosphate bindings, calcium supplements and active metabolite of Vitamin D) results in fact inadequate for over 50% of the hemodialysis patients.


Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:D'Angelo, Angela
Dottorato (corsi e scuole):Ciclo 20 > Scuole per il 20simo ciclo > SCIENZE MEDICHE, CLINICHE E SPERIMENTALI > NEFROLOGIA
Data di deposito della tesi:07 Novembre 2007
Anno di Pubblicazione:07 Novembre 2007
Parole chiave (italiano / inglese):iperparatiroidismo, uremia
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/14 Nefrologia
Struttura di riferimento:Dipartimenti > Dipartimento di Scienze Mediche e Chirurgiche
Codice ID:950
Depositato il:08 Ott 2008
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

(1) Rodriguez M., Nemeth E., Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol renal Physiol 288: F253-F264, 2005. Cerca con Google

(2) Drüeke T. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure (nephrology forum). 1995; 48: 259-72. Cerca con Google

(3) Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392. Cerca con Google

(4) Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59:1187-1201. Cerca con Google

(5) Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J kidney Dis 2000; 35:1226-1237. Cerca con Google

(6) National Kidney Foundation: K/DOQI clinical practice guidelines on bone metabolism and disease. Am J Kidney Dis 2003; 42(S3): 1-201 Cerca con Google

(7) Portale AA, Booth BE, Halloran BP, Morns RC Jr. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73: 1580-1589. Cerca con Google

(8) Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51:328-336. Cerca con Google

(9) Malberti F, Faina M, Imbasciati E. the PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999; 14:2398-2406. Cerca con Google

(10) Justin Silver, Rachel Kilav, Tally Naveh-Many. Mechanisms of secondary hyperparathyroidism. Am J Renal Physiol 2002; 283 F367-F376. Cerca con Google

(11) Gupta Ajay, Kallenbach Lee R., Zasuwa Gerard, Divine George W., Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Neprhol 2000; 11: 330-334. Cerca con Google

(12) Saleh F. N., Schirmer H., Sundsfjor J., Jorde R. Paratyroid hormone and left ventricular hypertrophy. European Heart Journal 2003; 24:2054-2060. Cerca con Google

(13) 16Urena P, Hruby M, Ferreira A et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512. Cerca con Google

(14) Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca x P product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138. Cerca con Google

(15) Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure. An evolving disorder. Kidney Int 1993; 43: 436-442. Cerca con Google

(16) Hsu CH, Potei SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999; 10: 1274-1280. Cerca con Google

(17) Young E, Satayathum S, Pisoni E, et al. Prevalence of values on mineral metabolism being outside the Targets from the Proposed New Draft NKF-K/DOQI and European Best Practice Guidelines in Countries of the Dialysis Outcomes and Practice Patterns Study (DOPPS) [abstract]. Nephrol Dial Transplant. 2003;18(4):677. Abstract W414. Cerca con Google

(18) Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New Eng J Med 2004; 350: 1516-1525. Cerca con Google

(19) Peacock M, Shoback DM, Greth WE, et al. The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT). J Bone Miner Res 2001; 16:S303. Cerca con Google

(20) Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95:4040-4045. Cerca con Google

(21) Harris RZ, Padhi D, Marbury TC, Noveck RJ, Salfi M, Sullivan JT. Pharmacokinetics, pharmacodynamic, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. . Am J Kidney Dis 2004; 44:1070-1076. Cerca con Google

(22) Peacock M, Shoback DM, Greth WE, et al. The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT). J Bone Miner Res 2001; 16:S303. Cerca con Google

(23) Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003. Cerca con Google

(24) Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New Eng J Med 2004; 350: 1516-1525. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record